DPP4 and hepatocellular carcinoma: After 28,071 person-years of follow-up, 832 cases of HCC were identified; the HCC incidence was lower among DPP-4 inhibitors users than non-DPP-4 inhibitors users (323.31 and 480.69 per 100,000 person-years, respectively).